SCHEMBL6663687

SCHEMBL6663687

Cc1ccc(-c2ccc3c(ccn3-c3cccnc3)c2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 6/20 0.49
CYP11B1 P15538 5/20 0.49
CYP2E1 P05181 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2A6 P11509 1/20 0.44
MDM2 Q00987 1/20 0.43
GRM1 Q13255 3/20 0.41
ROCK1 Q13464 1/20 0.40
FAAH O00519 1/20 0.40
CYP19A1 P11511 2/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CYP17A1 P05093 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6656915 0.89 CYP11B1 (0.50) CYP11B2CYP11B1CYP2E1CYP3A4CYP2A6
SCHEMBL6846113 0.89 CYP11B2 (0.48) CYP11B2CYP11B1CYP2E1CYP3A4CYP2A6
SCHEMBL6655119 0.89 CYP11B2 (0.51) CYP11B2CYP11B1CYP2E1CYP3A4CYP2A6
SCHEMBL17067754 0.88 ROCK1 (0.50) CYP11B2CYP11B1CYP2E1CYP3A4CYP2A6
SCHEMBL6846125 0.87 CYP11B2 (0.59) CYP11B2CYP11B1CYP3A4CYP2A6CYP19A1
SCHEMBL6682744 0.86 CYP11B2 (0.50) CYP11B2CYP11B1CYP2E1CYP3A4CYP2A6
SCHEMBL6662535 0.86 CYP19A1 (0.51) CYP11B2CYP11B1CYP3A4CYP19A1CYP17A1
SCHEMBL22515748 0.86 CYP11B2 (0.49) CYP11B2CYP11B1CYP2E1CYP3A4CYP2A6
SCHEMBL16538914 0.86 CYP11B2 (0.49) CYP11B2CYP11B1CYP2E1CYP3A4CYP2A6
SCHEMBL6656090 0.86 CYP11B2 (0.50) CYP11B2CYP11B1CYP3A4CYP19A1CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-11-25 US disclosed
EP-1432698-A2 SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS Bayer Pharmaceuticals Corporation (US) 2004-06-30 EP disclosed
WO-2003027094-A2 SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors CYP17A1, IDO1, CYP21A2 CYP11B2 53/4885CYP11B1 30/4885CYP2E1 143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.